



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



CS 2164

Item No. 38766

CAS Registry No.: 1256349-48-0
Formal Name: N-(2-aminophenyl)-6-[(7-methoxy-4-quinolinyl)oxy]-1-naphthalenecarboxamide
Synonyms: Chiauranib, Ibcasertib
MF: C₂₇H₂₁N₃O₃
FW: 435.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CS 2164 is supplied as a solid. A stock solution may be made by dissolving the CS 2164 in the solvent of choice, which should be purged with an inert gas. CS 2164 is soluble in methanol.

Description

CS 2164 is a multi-kinase inhibitor.¹ It inhibits VEGFR1, -2, and -3 (IC₅₀s = 8, 7, and 9 nM, respectively), PDGFRα and PDGFRβ (IC₅₀s = 1 and 93 nM), c-Kit (IC₅₀ = 4 nM), Aurora B kinase (IC₅₀ = 9 nM), and CSF-1 receptor tyrosine kinase (FMS; IC₅₀ = 7 nM). CS 2164 is selective for these kinases over a panel of 72 additional kinases, 76 GPCRs, two phosphatases, and nine ion channels (IC₅₀s = >100 nM for all). It inhibits VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; GI₅₀ = 20.7 nM) and PDGF-induced proliferation of NIH3T3 cells (GI₅₀ = 44.16 nM). *In vivo*, CS 2164 (20 mg/kg) reduces tumor vascularization and tumor growth in a COLO 320 colon cancer mouse xenograft model. It also reduces tumor volume in A549, HCT-8, SMMC-7721, and MGC803 mouse xenograft models when administered at doses ranging from 2.5 to 40 mg/kg.

Reference

1. Zhou, Y., Shan, S., Li, Z.-B., *et al.* CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. *Cancer Sci.* **108**(3), 469-477 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/30/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM